undamentalytics Newsletter
Sign in

Standard Biotools Inc. (LAB) stock

Add to watchlist

Add holding +

NASDAQ: LAB Nasdaq Life Sciences Tools & Services Next results ~November 3, 2026

Standard Biotools Inc. is a US-listed company in the life sciences tools & services industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: data-quality checks not passed.

Price vs value

Under review: data-quality checks not passed. We'll show the comparison once resolved.

Standard Biotools Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders4 buying, 0 selling15 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
  • Funds88 adding, 87 cuttingOf 32 active managers that changed their stake, 24 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Standard Biotools files

Where Standard Biotools stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $85m, down 4.8% on a year earlier, a steeper fall than the 3.7% decline a quarter earlier. Free-cash-flow margin rose to -97.6% from -118.7% a year earlier. Operating margin widened to -112.8% from -118.7%. The diluted share count is up 2.8% on a year earlier, which dilutes existing holders. It passes 2 of our 2 financial-health checks.

Our model value for Standard Biotools is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 5, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 3, 2026 (estimated)

Standard Biotools Inc.'s trailing-twelve-month revenue fell 4.8% year on year, with a free-cash-flow margin of -97.6%.

Current signal Net margin expanding: TTM net margin reached 100.4%, up 236.0pp year over year.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Margins widening. Operating margin is up 5.8 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.3bn.

Things to watch

  • Revenue shrinking. Revenue fell 4.8% over the last 12 months.
  • Loss-making. Operating margin is -112.8%: costs exceed revenue.
  • Burning cash. Free cash flow was -97.6% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 30.9% of revenue: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 2.8% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 68% and a beta of 1.1 against the S&P 500.

Latest results: FY2026 Q2

Filed August 5, 2026
Earnings per share
-$0.06 against an average estimate of -$0.03: missed by 100.0%
Revenue
$20m, down 7.6% on a year earlier
Share reaction
-2.4% in the first session after the results on August 5, 2026, against -0.4% for the S&P 500
Next report
November 3, 2026

Standard Biotools' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day0.0%
  • 1 week+1.7%
  • 1 month-17.6%
  • This year-52.3%
  • 1 year-49.2%
  • 5 years-88.1%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$84.6M
Operating margin
-112.8%
Net margin
100.4%
EPS (TTM, diluted)
$0.22

Growth

Revenue growth
−4.8%
Change in growth rate
−1.1 pts
Share count change
+2.8%

Cash

Free cash flow (TTM)
-$82.6M
FCF margin
-97.6%
Stock pay % of revenue
30.9%

Earnings

Last results
August 5, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Agreement
  3. Results
  4. Agreement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Standard Biotools Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: data-quality checks not passed.

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025Now
Share price$10.81$7.28$5.89$8.62$3.48$6.00$3.92$1.17$2.21$1.75$1.28$0.61
Market value$310m$211m$194m$342m$232m$432m$297m$92m$175m$618m$488m$236m
+ Net debt (− = net cash)$166m$160m−$58m$77m$32m−$14m$33m−$16m$12m−$166m−$121m−$270m
Enterprise value$476m$371m$136m$418m$265m$418m$330m$75m$187m$452m$368m−$34m
Multiples
Price / sales 2.7x2.0x1.9x3.0x2.0x3.1x2.3x0.9x1.6x6.8x5.7x2.8x
Price / earnings ———————————2.8x
Price / free cash flow ————————————
EV / EBITDA ————————————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

20 /100

Weak moat

How hard Standard Biotools's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Cash operating profit has been a median -7.5% of total assets over 6 years.

  • Pricing power 16 / 20

    Gross margin has been a median 50.2%, moving by 3.6 percentage points (standard deviation) across 6 years.

  • Durability 10 / 20

    Operating margin has been a median -76.2%; its worst year was -118.7%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 10 years, at a median -52.2% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 420.9% over five years; stock-based pay has been a median 11.7% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (26 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 3, 2026, after the close. Analysts expect revenue of $19m for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.10 +50% $83m −3%
Next −$0.16 −60% $82m −1%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −35.5% on 90 days ago. In the last 30 days, 0 analysts raised Standard Biotools Inc.'s forecast and 1 cut it.

Consensus EPS forecast Standard Biotools Inc., last 90 days
−$0.20 −$0.15 −$0.10 −$0.05 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.15 Current fiscal year, 60 days ago: −$0.16 Current fiscal year, 30 days ago: −$0.16 Current fiscal year, 7 days ago: −$0.16 Current fiscal year, Now: −$0.10 −$0.10 Next fiscal year, 90 days ago: −$0.14 Next fiscal year, 60 days ago: −$0.14 Next fiscal year, 30 days ago: −$0.13 Next fiscal year, 7 days ago: −$0.14 Next fiscal year, Now: −$0.16 −$0.16

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.15−$0.14
60 days ago −$0.16−$0.14
30 days ago −$0.16−$0.13
7 days ago −$0.16−$0.14
Now −$0.10−$0.16

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.03 −$0.06 −100.0%
Mar 2026 −$0.02 −$0.02 +15.5%
Dec 2025 −$0.03 $0.07 +368.8%
Sept 2025 −$0.02 −$0.04 −101.5%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 5, 2026

No numeric guidance in Standard Biotools Inc.'s latest earnings release (filed August 5, 2026). Some companies give their outlook only on the earnings call.

Analyst recommendations

1 analysts, Oct 2026
Buy00%
Hold1100%
Sell00%

Monthly trend

  1. Oct 202611

Counts of recommendations published by analysts covering Standard Biotools Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
1.0%
of tradable shares
Days to cover
2.55
at average volume
Short interest, 1 month
−6%
to October 15, 2026
Held by institutions
75%
of shares
Held by insiders
1.8%
of shares
Employees
385
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −49.2%

$1.20 on October 31, 2025 to $0.61

ThenNowEffect
Revenue (last 12 months) $89m $85m −4.8%
P/S multiple 5.1x 2.8x −45.1%
Share count 376m 387m −2.7%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
LAB−35%−70%+89%−21%−27%−52%
Industry peers (median)+5%−51%−3%−13%−2%+16%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
LAB42%25%50%33%50%46%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
LAB−51%−77%−48%−51%−55%−63%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 96% from March 20, 2019 to October 26, 2026. Getting back needed a 2293% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.60 – $1.68
From 52-week high
−63.7%
vs 50-day average
−10.2%
vs 200-day average
−33.0%
Volatility (1 year)
68%
Beta vs S&P 500
1.09

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
5 up, 7 down
typical move ±11.8%
After a week
4 up, 8 down
typical move ±11.7%
After a month
3 up, 9 down
typical move ±14.0%
Results releasedNext dayS&P 500 next day5 days21 days
August 5, 2026 −2.4% −0.4% −3.7% −18.3%
May 5, 2026 +3.2% +2.2% +7.4% +35.1%
February 24, 2026 +5.4% +1.6% −6.3% −13.5%
January 30, 2026 0.0% +0.2% −10.6% −26.2%
January 8, 2026 +20.3% +0.7% +23.4% −1.6%
November 4, 2025 −8.1% −0.8% −4.0% +16.1%
August 11, 2025 0.0% +0.9% −3.1% −2.3%
May 6, 2025 −11.3% −0.4% −0.9% −13.9%
February 26, 2025 −16.7% −1.5% −4.8% −9.5%
January 13, 2025 +23.3% +0.3% +15.3% −16.6%
October 30, 2024 +12.0% −2.3% +29.1% +5.1%
July 31, 2024 −38.8% +0.2% −31.9% −10.3%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Revenue (TTM) Standard Biotools Inc.
$80M $100M $120M $140M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $105.2M Revenue (TTM), FY23 Q4: $106.3M Revenue (TTM), FY24 Q1: $126.8M Revenue (TTM), FY24 Q2: $121.6M Revenue (TTM), FY24 Q3: $118.3M Revenue (TTM), FY24 Q4: $114.9M Revenue (TTM), FY25 Q1: $89.6M Revenue (TTM), FY25 Q2: $88.8M Revenue (TTM), FY25 Q3: $86.3M Revenue (TTM), FY25 Q4: $85.3M Revenue (TTM), FY26 Q1: $86.3M Revenue (TTM), FY26 Q2: $84.6M $84.6M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $105.2M
FY23 Q4 $106.3M
FY24 Q1 $126.8M
FY24 Q2 $121.6M
FY24 Q3 $118.3M
FY24 Q4 $114.9M
FY25 Q1 $89.6M
FY25 Q2 $88.8M
FY25 Q3 $86.3M
FY25 Q4 $85.3M
FY26 Q1 $86.3M
FY26 Q2 $84.6M
Revenue growth, TTM YoY Standard Biotools Inc.
-40% -20% 0% 20% 40% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: -3.7% Revenue growth, TTM YoY, FY23 Q4: 8.6% Revenue growth, TTM YoY, FY24 Q1: 31.3% Revenue growth, TTM YoY, FY24 Q2: 15.3% Revenue growth, TTM YoY, FY24 Q3: 12.5% Revenue growth, TTM YoY, FY24 Q4: 8.0% Revenue growth, TTM YoY, FY25 Q1: -29.3% Revenue growth, TTM YoY, FY25 Q2: -26.9% Revenue growth, TTM YoY, FY25 Q3: -27.0% Revenue growth, TTM YoY, FY25 Q4: -25.7% Revenue growth, TTM YoY, FY26 Q1: -3.7% Revenue growth, TTM YoY, FY26 Q2: -4.8% -4.8%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 -3.7%
FY23 Q4 8.6%
FY24 Q1 31.3%
FY24 Q2 15.3%
FY24 Q3 12.5%
FY24 Q4 8.0%
FY25 Q1 -29.3%
FY25 Q2 -26.9%
FY25 Q3 -27.0%
FY25 Q4 -25.7%
FY26 Q1 -3.7%
FY26 Q2 -4.8%
Operating margin (TTM) Standard Biotools Inc.
-150% -100% -50% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -72.6% Operating margin (TTM), FY23 Q4: -72.0% Operating margin (TTM), FY24 Q1: -94.8% Operating margin (TTM), FY24 Q2: -109.4% Operating margin (TTM), FY24 Q3: -117.1% Operating margin (TTM), FY24 Q4: -124.7% Operating margin (TTM), FY25 Q1: -122.8% Operating margin (TTM), FY25 Q2: -118.7% Operating margin (TTM), FY25 Q3: -129.4% Operating margin (TTM), FY25 Q4: -129.2% Operating margin (TTM), FY26 Q1: -111.0% Operating margin (TTM), FY26 Q2: -112.8% -112.8%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -72.6%
FY23 Q4 -72.0%
FY24 Q1 -94.8%
FY24 Q2 -109.4%
FY24 Q3 -117.1%
FY24 Q4 -124.7%
FY25 Q1 -122.8%
FY25 Q2 -118.7%
FY25 Q3 -129.4%
FY25 Q4 -129.2%
FY26 Q1 -111.0%
FY26 Q2 -112.8%
FCF margin (TTM) Standard Biotools Inc.
-150% -100% -50% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -49.4% FCF margin (TTM), FY23 Q4: -43.4% FCF margin (TTM), FY24 Q1: -78.8% FCF margin (TTM), FY24 Q2: -107.5% FCF margin (TTM), FY24 Q3: -125.5% FCF margin (TTM), FY24 Q4: -132.1% FCF margin (TTM), FY25 Q1: -138.3% FCF margin (TTM), FY25 Q2: -118.7% FCF margin (TTM), FY25 Q3: -114.0% FCF margin (TTM), FY25 Q4: -96.9% FCF margin (TTM), FY26 Q1: -109.5% FCF margin (TTM), FY26 Q2: -97.6% -97.6%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -49.4%
FY23 Q4 -43.4%
FY24 Q1 -78.8%
FY24 Q2 -107.5%
FY24 Q3 -125.5%
FY24 Q4 -132.1%
FY25 Q1 -138.3%
FY25 Q2 -118.7%
FY25 Q3 -114.0%
FY25 Q4 -96.9%
FY26 Q1 -109.5%
FY26 Q2 -97.6%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2009 Dec 2009 2010 Dec 2010 2011 Dec 2011 2012 Dec 2012 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 25 34 43 52 71 116 115 104 102 113 117 138 131 98 106 91 85 85
Gross profit — — 43 52 71 116 114 58 52 62 64 — — 37 50 45 43 43
EBITDA −16 −13 −17 −16 −16 −48 −45 −66 −51 −43 −47 −47 −64 −104 −64 −115 −101 −90
Operating income −18 −15 −19 −18 −19 −52 −50 −73 −58 −48 −52 −51 −67 −116 −77 −127 −110 −95
Net income −19 −17 −22 −19 −17 −53 −53 −76 −61 −59 −65 −53 −59 −190 −75 −139 −75 85
Diluted EPS −$1.10 −$0.89 −$1.81 −$0.86 −$0.65 −$1.90 −$1.86 −$2.62 −$1.84 −$1.49 −$0.97 −$0.74 −$0.78 −$2.43 −$0.94 −$0.52 −$0.20 $0.22
Growth (year on year)
Revenue — +32.1% +27.7% +22.1% +36.0% +63.6% −1.5% −8.9% −2.4% +10.8% +3.8% +17.8% −5.5% −25.0% +8.6% −14.4% −6.2% −4.8%
Margins
Gross margin — — 99.8% 99.4% 99.6% 99.7% 99.7% 55.9% 51.0% 54.6% 54.8% — — 37.8% 47.4% 49.3% 49.9% 50.5%
EBITDA margin −64.6% −40.0% −40.0% −30.3% −22.6% −41.0% −39.4% −63.6% −50.0% −37.9% −40.3% −34.0% −49.2% −105.9% −60.1% −126.3% −118.3% −106.4%
Operating margin −71.0% −43.4% −43.3% −34.5% −26.2% −44.5% −43.7% −70.1% −57.3% −42.6% −44.2% −36.9% −51.7% −118.6% −72.0% −140.1% −129.2% −112.8%
Net margin −75.3% −50.4% −52.4% −36.4% −23.2% −45.4% −46.5% −72.8% −59.4% −52.2% −55.3% −38.4% −45.4% −194.1% −70.2% −152.6% −87.8% 100.4%
Free-cash-flow margin −79.9% −38.9% −44.8% −38.0% −7.1% −25.8% −33.7% −42.3% −25.2% −22.6% −32.2% −20.4% −43.9% −95.1% −43.4% −166.8% −96.9% −97.6%
Cash flow
Cash from operations −20 −12 −18 −17 −2 −23 −35 −39 −24 −25 −35 −15 −44 −89 −43 −143 −74 −80
Capital spending 1 2 2 2 3 7 4 5 2 0 3 13 13 4 3 8 8 2
Free cash flow −20 −13 −19 −20 −5 −30 −39 −44 −26 −26 −38 −28 −57 −93 −46 −152 −83 −83
Stock-based pay 2 2 3 4 6 21 17 14 9 11 11 14 16 15 13 32 30 26
Free cash flow after stock pay −22 −15 −22 −24 −11 −51 −56 −58 −35 −37 −49 −43 −73 −108 −59 −184 −112 −109
Balance sheet
Cash 15 6 14 59 35 34 29 35 58 95 22 69 28 81 52 167 121 270
Total debt 0 18 10 0 0 195 195 195 — 172 54 54 61 65 64 0 0 0
Net debt (negative = net cash) −15 12 −3 −59 −35 162 166 160 −58 77 32 −14 33 −16 12 −166 −121 −270
Diluted shares — 19m 18m 22m 25m 28m 29m 29m 33m 40m 67m 72m 76m 78m 79m 353m 382m 387m
Returned to shareholders
Buybacks — — — — — — — — — — — — 0 1 5 40 0 —
Total returned — — — — — — — — — — — — 0 1 5 40 0 —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $627m
Short-term assets $517mLonger-term assets $110m
What it owes, and who funded it · $627m
Short-term liabilities $57mLonger-term liabilities $30mShareholders' equity $540m
  • Short-term assets cover short-term liabilities $517m of assets due within a year against $57m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $517m short-term assets against $30m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Standard Biotools Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2025 Q4 TTM
Buybacks (TTM)
$0
Returned to shareholders
0%
of free cash flow
Buybacks, last 3 fiscal years
$45.9M
Diluted share count
+2.8%
year over year
Total shareholder yield
0.0%
dividends 0.0% + buybacks 0.0% of market value
R&D spending
21.8%
of revenue
Sales & admin spending
102.8%
of revenue
Days sales outstanding
68 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in life sciences tools & services
Last 12 months unless stated LAB HBIO CDXS BNR XGN PSNL Median
Revenue, last 12 months $85m $88m $78m $75m $71m $70m $209m
Revenue growth, last 12 months −4.8% −1.1% 35.9% 4.7% 20.8% −13.3% 6.8%
Revenue growth, 3-year average −7.1% −8.4% −7.8% — 10.3% 1.2% 2.9%
Revenue growth, latest quarter −7.6% 11.1% −2.7% — 15.9% 30.0% 8.4%
Gross margin 50.5% 58.2% 87.0% 74.7% 58.6% 12.7% 51.2%
Operating margin −112.8% −0.3% −35.6% −10.2% −18.6% −164.1% −16.5%
Operating margin, 3-year average −113.6% −21.4% −81.6% — −23.4% −122.3% −23.3%
Net margin 100.4% −11.9% −39.6% −10.3% −26.6% −153.8% −12.2%
Cash from operations / revenue −94.9% 0.7% −13.4% −5.3% −9.1% −132.5% 0.7%
Free-cash-flow margin −97.6% −1.3% −15.7% −6.2% −10.7% −144.9% −3.1%
Free-cash-flow margin, 3-year average −107.9% 3.6% −71.6% — −16.3% −96.1% −0.4%
Stock pay / revenue 30.9% 1.6% 9.9% 2.6% 4.1% 15.7% 4.8%
Change in share count 2.8% 2.5% 12.9% −100.0% 23.9% 26.0% 1.0%

Median of all 55 companies we cover in life sciences tools & services. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue YoY
Products $61.7M ▼ 5.8%
Consumables $36.2M ▼ 10.6%
Instruments $25.4M ▲ 2.1%
Services and Other Revenue $23.7M ▼ 7.5%
Service and Other Revenue $23.7M ▼ 7.5%

These categories overlap or exclude eliminations, so shares aren't shown.

Geography
Region Revenue Share YoY
EMEA $36M 42.2% ▲ 0.9%
Americas $30.6M 35.8% ▼ 18.3%
Asia Pacific $18.8M 22.0% ▲ 4.6%

From Standard Biotools Inc.'s 10-K filed March 16, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$244M
Institutions reporting
143
Shares held vs prior quarter
▼ 0.4%
Positions opened / closed
42 / 51

Top buyers and sellers, Q2 2026: 88 institutions bought and 87 sold ; the biggest buyer was Long Focus Capital Management, LLC (+7.5M shares) and the biggest seller Blackrock, Inc (−16.5M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Casdin Capital, LLC $73M 88.8M 30.0% 0.0%
Viking Global Investors LP $48.3M 58.7M 19.8% 0.0%
Mak Capital One LLC $23.7M 28.8M 9.7% ▲ 10.1%
Long Focus Capital Management, LLC $19.3M 23.5M 7.9% ▲ 46.7%
Vanguard Capital Management LLC $10.1M 12.3M 4.1% ▼ 4.4%
Blackrock, Inc. $6.8M 8.3M 2.8% ▼ 66.7%
Hollow Brook Wealth Management LLC $4.5M 5.5M 1.9% ▼ 2.7%
Neuberger Berman Group LLC $4M 5.0M 1.7% ▲ 6.5%
Qube Research & Technologies Ltd $4M 4.8M 1.6% ▲ 584.3%
Royce & Associates LP $3.7M 4.5M 1.5% ▲ 50.6%
Geode Capital Management, LLC $3.2M 3.9M 1.3% ▼ 46.5%
Tikvah Management LLC $2.9M 3.6M 1.2% 0.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Standard Biotools Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $14.4M 15 trades by 4 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $14.4M net buying
Insider Date Trade Shares Price Value
Casdin Private Growth Equity Fund Gp, Llc Director December 4, 2025 Buy 150,000 $1.45 $217,500
Casdin Private Growth Equity Fund Gp, Llc Director December 3, 2025 Buy 75,000 $1.44 $108,000
Casdin Private Growth Equity Fund Gp, Llc Director December 2, 2025 Buy 125,000 $1.42 $177,500
Casdin Partners Gp, Llc Director November 25, 2025 Buy 7,550,000 $1.30 $9.8M
Casdin Partners Gp, Llc Director November 24, 2025 Buy 150,000 $1.43 $214,500
Casdin Eli Director November 20, 2025 Buy 450,000 $1.30 $585,000
Casdin Eli Director November 19, 2025 Buy 350,000 $1.28 $448,000
Casdin Eli Director November 18, 2025 Buy 275,000 $1.23 $338,250
Casdin Partners Master Fund, L.P. Director November 17, 2025 Buy 225,000 $1.22 $274,500
Casdin Partners Master Fund, L.P. Director November 14, 2025 Buy 250,000 $1.24 $310,000
Casdin Partners Master Fund, L.P. Director November 13, 2025 Buy 450,000 $1.20 $540,000
Casdin Partners Gp, Llc Director November 12, 2025 Buy 375,000 $1.19 $446,250

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

  • August 5, 2026
  • May 5, 2026
  • February 24, 2026
  • January 30, 2026
  • January 8, 2026
  • November 4, 2025

Recent SEC filings

Data status

When each part of this page on Standard Biotools Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Standard Biotools Inc. in brief

What does Standard Biotools Inc. do?
Standard Biotools Inc. is a US-listed company in the life sciences tools & services industry. Its financial year ends in December.
What is Standard Biotools Inc.'s stock ticker?
Standard Biotools Inc. trades under the ticker LAB on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Standard Biotools Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Standard Biotools Inc. reported revenue of $84.6M, 4.8% lower than a year earlier, according to its SEC filings.
What is Standard Biotools Inc.'s free cash flow?
Standard Biotools Inc.'s free-cash-flow margin is -97.6% of revenue over the trailing twelve months.
Who are Standard Biotools Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Casdin Capital, LLC, Viking Global Investors LP and Mak Capital One LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is Standard Biotools Inc. buying back stock, and does it pay a dividend?
Standard Biotools Inc. spent $0 on share repurchases over the trailing twelve months, and its diluted share count still rose 2.8% over the year.
What is Standard Biotools Inc.'s market cap?
On November 2, 2026, Standard Biotools Inc.'s market capitalisation was about $236M, with a price-to-earnings ratio of 2.8 and net debt of -$270M. Market figures come from third-party market data and may be delayed.
Who are Standard Biotools Inc.'s competitors?
In our Life Sciences Tools & Services peer group, the companies closest to Standard Biotools Inc. are Harvard Bioscience Inc, Codexis, Inc., Burning Rock Biotech Ltd, Exagen Inc. and Personalis, Inc. The side-by-side comparison below sets their revenue, margins and growth against Standard Biotools Inc.'s.
Are insiders buying or selling Standard Biotools Inc. stock?
Over the last 12 months, Standard Biotools Inc.'s directors and officers reported 15 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
When is Standard Biotools Inc.'s next earnings date?
Around November 3, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Standard Biotools Inc. announces its own schedule.